Abeona Therapeutics (ABEO)

$5.25 -0.20 (-3.67%)
Market Cap 281.25M
Revenue (ttm) 0.00
Net Income (ttm) -63.73M
EPS (ttm) N/A
PE Ratio 4.50
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.12
Volume 2,155,600
Avg Vol 1,747,036
Day's Range N/A - N/A
Shares Out 54.19M
Stochastic %K 89%
Beta 1.12
Analysts Strong Sell
Price Target $20.64

Company Profile

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based g...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 813 4701
Address:
6555 Carnegie Avenue, 4th Floor, Cleveland, United States
HedgiesLivesMatter
HedgiesLivesMatter Jan. 17 at 12:12 AM
$ABEO
0 · Reply
bentley99
bentley99 Jan. 16 at 8:55 PM
$ABEO Just when I was ignoring a swing position here.
0 · Reply
Po556677
Po556677 Jan. 16 at 8:23 PM
$ABEO Come on Market Makers bought 30k on the dip have another 20k to buy \DROP IT MORE
0 · Reply
FitzCatalyst
FitzCatalyst Jan. 16 at 8:22 PM
$ABEO someone know something. Better not get an ah surprise
1 · Reply
creditgoo
creditgoo Jan. 16 at 8:21 PM
$ABEO easy short
0 · Reply
Orlandotrader
Orlandotrader Jan. 16 at 8:17 PM
$ABEO Company Execution Paramount going Foward. Let’s Line up the Therapy Boyz!!!!!
0 · Reply
Po556677
Po556677 Jan. 16 at 8:12 PM
$ABEO Cantor just raised its price target to 28!!!! Let that sink in........buying
0 · Reply
creditgoo
creditgoo Jan. 16 at 8:09 PM
$ABEO lmao down 40 cents
1 · Reply
alexpitti
alexpitti Jan. 16 at 8:09 PM
$ABEO just tanks out of nowhere. im sure related to options. sucks
0 · Reply
Po556677
Po556677 Jan. 16 at 7:53 PM
$ABEO Blatant Manulaption.....clear as day
0 · Reply
Latest News on ABEO
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 31, 2025, 7:30 AM EST - 16 days ago

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer

Dec 15, 2025, 7:30 AM EST - 4 weeks ago

Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas

Dec 11, 2025, 7:30 AM EST - 5 weeks ago

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas

Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy

Dec 8, 2025, 7:30 AM EST - 5 weeks ago

Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy

Abeona Therapeutics Q3 2025: Strong Financials And Zevaskyn Launch Ahead

Nov 12, 2025, 2:52 PM EST - 2 months ago

Abeona Therapeutics Q3 2025: Strong Financials And Zevaskyn Launch Ahead

Abeona Therapeutics Inc. (ABEO) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 12:11 PM EST - 2 months ago

Abeona Therapeutics Inc. (ABEO) Q3 2025 Earnings Call Transcript

Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates

Nov 12, 2025, 7:30 AM EST - 2 months ago

Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates

Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation

Nov 7, 2025, 7:30 AM EST - 2 months ago

Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation

Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)

Oct 30, 2025, 10:45 AM EDT - 2 months ago

Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)

Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs

Oct 20, 2025, 8:30 AM EDT - 3 months ago

Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs

Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program

Oct 13, 2025, 7:30 AM EDT - 3 months ago

Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program

Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy

Oct 8, 2025, 7:30 AM EDT - 3 months ago

Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Aug 29, 2025, 7:30 AM EDT - 5 months ago

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Abeona Therapeutics Inc. (ABEO) Q2 2025 Earnings Call Transcript

Aug 19, 2025, 3:25 PM EDT - 5 months ago

Abeona Therapeutics Inc. (ABEO) Q2 2025 Earnings Call Transcript

Abeona Therapeutics: AAV204 Capsid Could Be Next Growth Prospect Beyond Zevaskyn

Aug 15, 2025, 4:36 PM EDT - 5 months ago

Abeona Therapeutics: AAV204 Capsid Could Be Next Growth Prospect Beyond Zevaskyn

Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates

Aug 14, 2025, 7:30 AM EDT - 5 months ago

Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates

AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients

Jul 29, 2025, 10:00 AM EDT - 6 months ago

AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients

ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area

Jul 15, 2025, 7:30 AM EDT - 6 months ago

ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area

Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy

Jul 14, 2025, 7:00 AM EDT - 6 months ago

Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy

TECH

Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million

Jul 2, 2025, 7:30 AM EDT - 7 months ago

Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million

Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy

Jul 1, 2025, 7:30 AM EDT - 7 months ago

Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy

Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index

Jun 30, 2025, 7:30 AM EDT - 7 months ago

Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index

Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa

Jun 24, 2025, 7:30 AM EDT - 7 months ago

Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade)

Jun 5, 2025, 5:48 AM EDT - 8 months ago

Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade)

Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference

May 30, 2025, 8:46 AM EDT - 8 months ago

Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference

Abeona Therapeutics Inc. (ABEO) Q1 2025 Earnings Call Transcript

May 16, 2025, 1:37 AM EDT - 8 months ago

Abeona Therapeutics Inc. (ABEO) Q1 2025 Earnings Call Transcript

Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates

May 15, 2025, 7:30 AM EDT - 8 months ago

Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates

UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

May 14, 2025, 8:07 AM EDT - 8 months ago

UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder

May 14, 2025, 7:30 AM EDT - 8 months ago

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

May 14, 2025, 7:30 AM EDT - 8 months ago

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million

May 12, 2025, 7:30 AM EDT - 8 months ago

Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million

Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease

Apr 30, 2025, 4:41 PM EDT - 9 months ago

Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease

US FDA approves Abeona's skin disorder therapy

Apr 29, 2025, 6:06 AM EDT - 9 months ago

US FDA approves Abeona's skin disorder therapy

U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Apr 29, 2025, 6:00 AM EDT - 9 months ago

U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Undercovered Dozen: 3D Systems, Seritage, Topicus, Timken +

Apr 27, 2025, 8:30 AM EDT - 9 months ago

Undercovered Dozen: 3D Systems, Seritage, Topicus, Timken +

DDD TKR KARO NNDM ORC PAA PAGP

Pz-Cel Has Massive Potential For RDEB Patients

Apr 21, 2025, 10:00 AM EDT - 9 months ago

Pz-Cel Has Massive Potential For RDEB Patients

Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher

Apr 12, 2025, 11:39 AM EDT - 9 months ago

Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher

Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 3:20 PM EDT - 10 months ago

Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript

Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans

Mar 20, 2025, 7:30 AM EDT - 10 months ago

Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans

Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference

Mar 4, 2025, 9:00 AM EST - 11 months ago

Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference

Abeona Therapeutics: Despite Some Competitive Pressure, This Looks Undervalued

Jan 24, 2025, 12:40 PM EST - 1 year ago

Abeona Therapeutics: Despite Some Competitive Pressure, This Looks Undervalued

Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Nov 14, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Nov 12, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics® Announces Participation in November Investor Conferences

Nov 4, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics® Announces Participation in November Investor Conferences

Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration

Abeona Therapeutics Targets RDEB Market With Promising Pz-cel Therapy

Oct 3, 2024, 8:09 AM EDT - 1 year ago

Abeona Therapeutics Targets RDEB Market With Promising Pz-cel Therapy

Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors

Aug 14, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors

Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel

Aug 13, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel

Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission

Aug 12, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission

Abeona: BLA Resubmission Of Pz-Cel Gets Ball Rolling Towards Other Milestones

Jul 12, 2024, 4:59 PM EDT - 1 year ago

Abeona: BLA Resubmission Of Pz-Cel Gets Ball Rolling Towards Other Milestones

HedgiesLivesMatter
HedgiesLivesMatter Jan. 17 at 12:12 AM
$ABEO
0 · Reply
bentley99
bentley99 Jan. 16 at 8:55 PM
$ABEO Just when I was ignoring a swing position here.
0 · Reply
Po556677
Po556677 Jan. 16 at 8:23 PM
$ABEO Come on Market Makers bought 30k on the dip have another 20k to buy \DROP IT MORE
0 · Reply
FitzCatalyst
FitzCatalyst Jan. 16 at 8:22 PM
$ABEO someone know something. Better not get an ah surprise
1 · Reply
creditgoo
creditgoo Jan. 16 at 8:21 PM
$ABEO easy short
0 · Reply
Orlandotrader
Orlandotrader Jan. 16 at 8:17 PM
$ABEO Company Execution Paramount going Foward. Let’s Line up the Therapy Boyz!!!!!
0 · Reply
Po556677
Po556677 Jan. 16 at 8:12 PM
$ABEO Cantor just raised its price target to 28!!!! Let that sink in........buying
0 · Reply
creditgoo
creditgoo Jan. 16 at 8:09 PM
$ABEO lmao down 40 cents
1 · Reply
alexpitti
alexpitti Jan. 16 at 8:09 PM
$ABEO just tanks out of nowhere. im sure related to options. sucks
0 · Reply
Po556677
Po556677 Jan. 16 at 7:53 PM
$ABEO Blatant Manulaption.....clear as day
0 · Reply
FitzCatalyst
FitzCatalyst Jan. 16 at 7:46 PM
$ABEO
0 · Reply
creditgoo
creditgoo Jan. 16 at 7:45 PM
$ABEO lol always sells off
1 · Reply
No0b_investor
No0b_investor Jan. 16 at 6:43 PM
$ABEO my prediction is that it will be USD 7.5 after the Q4 earnings release.
0 · Reply
Orlandotrader
Orlandotrader Jan. 16 at 5:02 PM
$ABEO Can’t keep denying us forever!!! At the 200. Typically a News Event will Gap us above with Large Volume!!! Wait for it.
0 · Reply
gusm17
gusm17 Jan. 16 at 4:25 PM
$ABEO load up - someone trying to get $1M +
1 · Reply
Barackodoma
Barackodoma Jan. 16 at 3:24 PM
$ABEO what type of revenue are we looking for this company to report this quarter or next to see significant movement?
1 · Reply
FitzCatalyst
FitzCatalyst Jan. 16 at 3:18 PM
$ABEO our time is coming. Just one January update pr away from full “game on” mode
1 · Reply
MarketPro
MarketPro Jan. 16 at 2:49 PM
$ABEO Buy Signal / Daily Chart
1 · Reply
acm20
acm20 Jan. 16 at 2:41 PM
$ABEO
0 · Reply
Orlandotrader
Orlandotrader Jan. 16 at 2:40 PM
$ABEO Breakout Imminent.
0 · Reply
Filvul
Filvul Jan. 16 at 12:51 PM
$ABEO
0 · Reply
FitzCatalyst
FitzCatalyst Jan. 16 at 11:30 AM
$ABEO
0 · Reply